Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: Findings from the scleroderma lung study

Chest

Volumn 142, Issue 3, 2012, Pages 614-621

  Theodore, Arthur C ^a   Tseng, Chi Hong ^c   Li, Ning ^b   Elashoff, Robert M ^c   Tashkin, Donald P ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE ACTIVITY; DISEASE SEVERITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HEARTBURN; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CAPACITY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; SCLERODERMA INTERSTITIAL LUNG DISEASE; SPUTUM; SYMPTOMATOLOGY; TOTAL LUNG CAPACITY; TREATMENT RESPONSE;

EID: 84865858892     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0801     Document Type: Article

References (33)

1. Tashkin DP, Elashoff R, Clements PJ, et al Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655-2666.
2. Tashkin DP, Elashoff R, Clements PJ, et al Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026-1034. (Pubitemid 350127847)
3. Widdicombe JG. Afferent receptors in the airways and cough. Respir Physiol. 1998;114(1):5-15. (Pubitemid 28526639)
4. Lalloo UG, Lim S, DuBois R, Barnes PJ, Chung KF. Increased sensitivity of the cough reflex in progressive systemic sclerosis patients with interstitial lung disease. Eur Respir J. 1998;11(3):702-705. (Pubitemid 28194865)
5. Hanácek J, Davies A, Widdicombe JG. Influence of lung stretch receptors on the cough reflex in rabbits. Respiration. 1984;45(3):161-168. (Pubitemid 14075455)
6. Karlsson JA. The role of capsaicin-sensitive C-fibre afferent nerves in the cough reflex. Pulm Pharmacol. 1996;9(5-6):315-321.
7. Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991;18(10):1520- 1528.
8. Remy-Jardin M, Remy J, Wallaert B, Bataille D, Hatron PY. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology. 1993;188(2):499-506. (Pubitemid 23216278)
9. Behr J, Vogelmeier C, Beinert T, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med. 1996;154(2 pt 1):400-406. (Pubitemid 26269110)
10. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung dis ease using bronchoalveolar lavage. Am J Med. 1990;88(5):470-476. (Pubitemid 20168722)
11. Wallaert B, Hatron PY, Grosbois JM, Tonnel AB, Devulder B, Voisin C. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relation ship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis. 1986;133(4):574-580. (Pubitemid 16127240)
12. Witt C, Borges AC, John M, Fietze I, Baumann G, Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis. 1999;58(10):635-640. (Pubitemid 29468032)
13. Goldin JG, Lynch DA, Strollo DC, et al Scleroderma Lung Study Research Group. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008;134(2):358-367.
14. Goldin JG, Elashoff R, Kim HJ, et al. Treatment of scleroderma- interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009;136(5):1333-1340.
15. Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007;56(6):2005-2012. (Pubitemid 47110399)
16. Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L. Per sistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Arthritis Rheum. 2007;56(12):4195-4202. (Pubitemid 350262348)
17. Westcott JL, Cole SR. Traction bronchiectasis in end-stage pulmonary fibrosis. Radiology. 1986;161(3):665-669. (Pubitemid 17200414)
18. Subcommittee for Scleroderma Criteria of the American Rheu matism Association Diagnostic and Therapeutic Criteria Com mittee. Preliminary criteria for the classification of systemic sclerosis(scleroderma). Arthritis Rheum. 1980;23(5):581-590.
19. Miller WT Jr, Shah RM. Isolated diffuse ground-glass opacity in thoracic CT: causes and clinical presentations. Am J Roentgenol. 2005;184(2):613-622. (Pubitemid 46657274)
20. Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol. 1998;25(1):84-88. (Pubitemid 28060123)
21. Strange C, Bolster MB, Roth MD, et al Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008;177(1):91-98.
22. Petty TL. The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest. 1990;97(1):75-83. (Pubitemid 20023495)
23. Khanna D, Clements PJ, Furst DE, et al Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum. 2005;52(2):592-600. (Pubitemid 40216324)
24. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483.
25. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751-758. (Pubitemid 14121920)
26. Furst DE, Tseng C-H, Clements PJ, et al Scleroderma Lung Study. Adverse events during the Scleroderma Lung Study. Am J Med. 2011;124(5):459-467.
27. Clements PJ, Goldin JG, Kleerup EC, et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum. 2004;50(6):1909-1917. (Pubitemid 38728980)
28. Clements PJ, Roth MD, Elashoff R, et al Scleroderma Lung Study Group. Scleroderma lung study(SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007;66(12):1641-1647. (Pubitemid 350205454)
29. Miller KS, Smith EA, Kinsella M, Schabel SI, Silver RM. Lung disease associated with progressive systemic sclerosis. Assessment of interlobar variation by bronchoalveolar lavage and comparison with noninvasive evaluation of disease activity. Am Rev Respir Dis. 1990;141(2):301-306. (Pubitemid 20068864)
30. Kim HG, Tashkin DP, Clements PJ, et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol. 2010;28(5 suppl 62):S26-S35.
31. Kowal-Bielecka O, Kowal K, Rojewska J, et al. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis. 2005;64(9):1343-1346. (Pubitemid 41206254)
32. Cole JC, Khanna D, Clements PJ, et al. Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index(HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res. 2006;15(8):1383-1394. (Pubitemid 44673612)
33. Khanna D, Yan X, Tashkin DP, et al Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007;56(5):1676-1684. (Pubitemid 46764099)